CEO Leonard Mazur
to present on Tuesday, September 10,
2024, at 9:00 am ET
CRANFORD, N.J., Sept. 5,
2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced
that Chairman and CEO Leonard Mazur will present and host
one-on-one investor meetings at the H.C. Wainwright & Co.
26th Annual Global Investment Conference taking place
September 9–11, 2024, in New York
City.
H.C. Wainwright Conference
Details:
|
Presentation:
|
9:00 am ET on Tuesday,
September 10, 2024*
|
|
Location:
|
Lotte New York Palace
Hotel, New York City
|
|
Registration:
|
Available on the
conference website.
|
|
1x1
meetings:
|
Requests available upon
registration or by contacting Citius Investor Relations.
|
|
|
|
Webcast:
|
Join live
here.
|
*Please note that the presentation date and time are subject to
change. Participants should refer to the final program agenda for
up-to-date information.
Recent Business Developments:
During his presentation and investor meetings, Mr. Mazur will
discuss recent business developments including:
- FDA Approval of LYMPHIR™ (denileukin diftitox-cxdl), an
immunotherapy for the treatment of cutaneous T-cell lymphoma
(CTCL);
- Merger of the Company's subsidiary with TenX Keane to form
publicly listed Citius Oncology, Inc. (Nasdaq: CTOR); and,
- Achieving primary and secondary endpoints in the completed
Phase 3 Pivotal Trial of Mino-Lok®, an antibiotic
lock solution designed to salvage central venous catheters in
patients with catheter-related bloodstream infections.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a
biopharmaceutical company dedicated to the development and
commercialization of first-in-class critical care products. In
August 2024, the FDA approved
LYMPHIR, a targeted immunotherapy for an initial indication in the
treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage
pipeline also includes Mino-Lok®, an antibiotic lock
solution to salvage catheters in patients with catheter-related
bloodstream infections, and CITI-002 (Halo-Lido), a topical
formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial
for Mino-Lok and a Phase 2b trial for
Halo-Lido were completed in 2023. Mino-Lok met primary and
secondary endpoints of its Phase 3 Trial. Citius is actively
engaged with the FDA to outline next steps for both programs.
Citius Pharmaceuticals owns approximately 90% of Citius Oncology.
For more information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239745.html
SOURCE Citius Pharmaceuticals, Inc.